Nadroparin calcium - Misplaced Pages

(Redirected from Nadroparin) Chemical compound Pharmaceutical compound

Nadroparin calcium
Clinical data

Trade names	Fraxiparin(e), Fraxodi, others
AHFS/Drugs.com	International Drug Names
Routes of administration	Subcutaneous injection (except for haemodialysis)
ATC code	B01AB06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only
Pharmacokinetic data
Bioavailability	89% (SC dose)
Elimination half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
IUPAC name (4S,6R)-6-oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
CAS Number	9005-49-6
DrugBank	DB08813
ChemSpider	none
UNII	1K5KDI46KZ
KEGG	D07510
CompTox Dashboard (EPA)	DTXSID20872761
ECHA InfoCard	100.029.698
Chemical and physical data
Molar mass	4300 g/mol
(what is this?) (verify)

Nadroparin (trade names Fraxiparin, Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the World Health Organization's List of Essential Medicines.

References

"Fraxiparine PRODUCT MONOGRAPH (Canada)" (PDF). Aspripharma.com. Retrieved 2 April 2019.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

External links

"NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 2 April 2019.
Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban Tirofiban
ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor
Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil
COX inhibitors	Acetylsalicylic acid/Aspirin Aloxiprin Carbasalate calcium Indobufen Triflusal
Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban
Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal
Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low-molecular-weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin Oligosaccharides Fondaparinux Idraparinux Heparinoids Danaparoid Dermatan sulfate Sulodexide
Direct Xa inhibitors ("xabans")	Apixaban Betrixaban Darexaban Edoxaban Otamixaban Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories: